Hepatic angiosarcoma and liver transplantation: case report and literature review

Huerta-Orozco, Lorena Denisse; Leonher-Ruezga, Karla Lisseth; Ramírez-González, Luis Ricardo; Hermosillo-Sandoval, José Manuel; Sandoval-Alvarado, José de Jesús; Morán-Galaviz, Rubén Eduardo

doi:10.1016/j.circen.2015.11.016

Cited by 4 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This way, HA may mimic cavernous haemangiomas [ 12 ]. The surrounding hepatocytes may be hyperplastic or atrophic [ 7 , 24 , 27 ]. The hyperplastic hepatocytes with the irregular dilated lining of the cells and atypical sinusoids are believed to show early changes, while the atrophy of hepatocytes is supposed to indicate a progressive HA [ 23 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…The disease might also manifest with acute liver failure or spontaneous rupture of the tumor, but these are rare conditions compared to complaints of nonspecific symptoms, such as right upper quadrant pain, fatigue, weakness and weight loss [ 1 , 5 , 6 ]. Therefore, the tumor is often discovered at an advanced stage with an average diameter of 15 – 65 mm [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma – Rare, Challenging and Fatal. Case Report and Literature Review

Strainiene

Jauniškis

Savlan

et al. 2021

AML

View full text Add to dashboard Cite

Background. Hepatic angiosarcoma is an uncommon, malignant, primary liver tumor, comprising 2% of liver cancers and accounting for < 1% of all sarcomas. Patients usually present with nonspecific symptoms, such as fatigue, weight loss, right upper quadrant pain, anemia, which leads to late diagnosis of an advanced stage tumor. The median life expectancy after the diagnosis of hepatic angiosarcoma is about 6 months, with only 3% of patients surviving more than 2 years. Liver failure and hemoperitoneum are the leading causes of death in patients with liver angiosarcoma. In rarer cases, it might cause paraneoplastic syndromes such as disseminated intravascular coagulopathy. The treatment of angiosarcomas is complicated as there are no established and effective treatment guidelines due to the tumor’s low frequency and aggressive nature.Case summary. We present the case of a 68-year old woman who was admitted to the hospital due to fatigueand severe anemia (hemoglobin 65 g/l). Laboratory results also revealed high-grade thrombocytopenia(8 × 109/l). The abdominal ultrasound and computed tomography scan showed multiple lesions throughout with hepatic angiosarcoma. The treatment with first-line chemotherapy (doxorubicin) was initiated despiteongoing paraneoplastic syndrome – disseminative intravascular coagulopathy. However, the disease was terminal, and the patient died 2 months since diagnosed.Conclusions. Hepatic angiosarcoma is a rare and terminal tumor. Therefore, knowledge about its manifestations and effective treatment methods is lacking. Disseminative intravascular coagulopathy is a unique clinical characteristic of angiosarcoma seen in a subset of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma – Rare, Challenging and Fatal. Case Report and Literature Review

Strainiene

Jauniškis

Savlan

et al. 2021

AML

View full text Add to dashboard Cite

show abstract

“…There are no specific tumour markers for hepatic angiosarcoma with patients usually having normal or slightly elevated alpha-fetoprotein or cancer antigen 19–9 levels 16. It is often difficult to diagnose hepatic angiosarcoma due to a lack of specific findings on imaging but the majority of tumours show multiple nodules and dominant masses with necrosis and haemorrhage on CT and MRI.…”

Section: Discussionmentioning

confidence: 99%

Hepatic angiosarcoma as a cause of acute liver failure

Singh¹,

Mills

Asadi

et al. 2018

BMJ Case Reports

View full text Add to dashboard Cite

Hepatic angiosarcoma is an extremely rare disease entity that accounts for approximately 0.1%-2% of primary liver malignancy. It is three times more common in men than women and usually affects the former in their sixth or seventh decade of life. Risk factors for the development of hepatic angiosarcoma include the use of oral contraceptives, exposure to anabolic steroids, radiation, thorium dioxide, arsenic and vinyl chloride. The prognosis of hepatic angiosarcoma is extremely poor which is attributable to early metastases to other organs, resistance to traditional chemotherapy and radiotherapy regimens and rapid progression of the tumour. Optimal management of patients is poorly demarcated due to the rarity of the tumour. We present a case series of two patients: one who passed away due to acute hepatic failure secondary to hepatic angiosarcoma and the second who underwent a liver transplantation and was subsequently diagnosed with hepatic angiosarcoma based on his explant histology.

show abstract

“…9 It was shown to increase the risk of HAS 10-15-fold, with a latency period of 9-35 years. 10,11 Cases of vinyl chloride monomerinduced HAS are now less common, with worldwide regulations on its emission having been established. 12 In addition, arsenic is also known to cause HAS and is found in contaminated drinking water and pesticides, or used in Fowler's solution to treat asthma, psoriasis, and other conditions.…”

Section: Epidemiology and Aetiologymentioning

confidence: 99%

“…30 Hypercalcaemia can be elevated in cases associated with bone metastases. 17 There are no specific tumour markers associated with HAS; carcinoembryonic antigen, 23 alpha-fetoprotein, and cancer antigen 19-9 may show mild elevations, 11 but none are specific to HAS.…”

Section: Investigationsmentioning

confidence: 99%

Primary Hepatic Angiosarcoma: A Brief Review of the Literature

Chen

Jung

2018

EMJ Hepatol

View full text Add to dashboard Cite

Primary hepatic angiosarcoma (HAS) is a liver tumour of endothelial cell origin. It is the most common malignant mesenchymal tumour of the liver, but is nonetheless rare, accounting for approximately 0.1–2.0% of all primary liver malignancies. Historically, 25% of HAS cases were associated with occupational or medicinal exposure, but most cases are now considered idiopathic. Patients present with vague signs and symptoms of liver disease, often resulting in late diagnoses; patients may present with acute liver failure or spontaneous rupture of the tumour, but this is rare. Preoperative diagnosis of HAS is difficult because laboratory and radiological findings are often non-specific or unable to discern malignant masses from benign growths. Obtaining a biopsy for histopathological diagnosis of HAS is also difficult because of its vascular and haemorrhagic nature, and reports of death from closed biopsies have been noted. Prognosis is poor because of the disease’s diagnostic challenges and the tumour’s rapidly progressive and early metastatic nature. The reported median survival is approximately 6 months, with only 3% of patients living >2 years. This paper will review and summarise new and existing publications in the English language literature to provide a better understanding of the challenges posed by HAS.

show abstract

Hepatic angiosarcoma and liver transplantation: case report and literature review

Cited by 4 publications

References 13 publications

Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma – Rare, Challenging and Fatal. Case Report and Literature Review

Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma – Rare, Challenging and Fatal. Case Report and Literature Review

Hepatic angiosarcoma as a cause of acute liver failure

Primary Hepatic Angiosarcoma: A Brief Review of the Literature

Contact Info

Product

Resources

About